OR WAIT 15 SECS
Brammer Bio establishes late-phase development and commercial manufacturing facility for advanced cell and gene therapies in Lexington, MA.
Brammer Bio, a cell and gene therapy contract development and manufacturing organization, announced on June 8, 2016 plans to build-out a 50,000-sq-ft. facility for late phase development, including Phase III and commercial production, of viral vector-based and cell-based advanced therapies. The Lexington, MA, facility will be qualified and operational by Q2 of 2017.
After completing a merger with Florida Biologix in March 2016, the CDMO will further solidify its leading technical and operational supply position through the build-out of the Lexington, MA, facility.
Brammer Bio completed a merger with Florida Biologix in March 2016 and is building on Florida Biologix’s ten-year record of manufacturing and testing to support clinical trials of advanced therapeutics, the company reports.
The addition of large-scale and late-stage manufacturing at the Lexington facility, in conjunction with the early clinical focus of the Florida location, will provide clients with the start-to-finish capability of manufacturing and testing advanced cell and gene therapies, according to a company statement.
Brammer Bio is looking to grow the Lexington workforce by up to 200, employing engineers and scientists, and specialists.
Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications, along with process and analytical development, and regulatory support for large pharma and biotech clients.
Source: Brammer Bio